How Evolocumab (Repatha) Affects AST Levels

What FOURIER Showed About AST and Evolocumab

The largest safety dataset for evolocumab comes from the FOURIER trial, which randomized 27,564 patients with stable atherosclerotic cardiovascular disease to evolocumab 140 mg every two weeks (or 420 mg monthly) versus placebo, on top of optimized statin therapy 1. The primary endpoint was cardiovascular events, but the trial's safety analysis captured liver enzyme changes across the full cohort over a median follow-up of 2.2 years.

AST elevations exceeding three times the upper limit of normal (>3× ULN) occurred at a rate of approximately 1.0% in the evolocumab arm versus 1.0% in the placebo arm. That difference was not statistically significant. Hepatic serious adverse events were equally rare in both groups. These findings held true regardless of whether patients were taking high-intensity statins (atorvastatin 40-80 mg or rosuvastatin 20-40 mg), which themselves carry a well-documented association with transaminase elevation 2.

The FOURIER investigators noted no dose-dependent pattern in liver enzyme abnormalities, and no patients discontinued evolocumab specifically because of hepatotoxicity attributed to the drug. That clean signal across nearly 28,000 patients over two years represents some of the strongest hepatic safety data available for any lipid-lowering biologic.

Why PCSK9 Inhibition Does Not Directly Raise AST

AST (aspartate aminotransferase) rises when hepatocytes or muscle cells are damaged and leak intracellular enzymes into the bloodstream. The mechanism of evolocumab offers a clear explanation for why this does not happen. Evolocumab is a fully human IgG2 monoclonal antibody that binds circulating PCSK9 protein in the bloodstream 3. By neutralizing PCSK9, the drug prevents the degradation of LDL receptors on the hepatocyte surface, allowing more LDL-C clearance from plasma.

This process upregulates LDL receptor recycling. It does not alter hepatocyte membrane integrity, mitochondrial function, or bile acid metabolism. Statins, by contrast, inhibit HMG-CoA reductase inside the hepatocyte, which is why they occasionally trigger dose-dependent transaminase leaks. Evolocumab works entirely outside the cell. The antibody never enters the hepatocyte cytoplasm, and no downstream signaling pathway linked to PCSK9 inhibition has been shown to provoke hepatocellular injury in preclinical or clinical studies 4.

A 2016 pooled analysis of 6,026 patients from four phase III PROFICIO trials (LAPLACE-2, RUTHERFORD-2, GAUSS-2, and DESCARTES) confirmed that ALT and AST elevations >3× ULN were no more frequent with evolocumab than placebo 5. This consistency across heterogeneous populations (statin-tolerant, statin-intolerant, familial hypercholesterolemia) reinforces that the safety signal is genuinely neutral.

AST Versus ALT: Which Matters More for Liver Monitoring?

AST is less liver-specific than ALT. AST exists in high concentrations in cardiac muscle, skeletal muscle, kidneys, and red blood cells, not only in the liver. A patient on Repatha who presents with an isolated AST elevation (ALT normal) is far more likely experiencing a musculoskeletal source, exercise effect, or hemolysis artifact than drug-induced liver injury (DILI).

ALT is the more hepatocyte-specific marker. The American College of Cardiology and American Heart Association lipid guidelines reference ALT, not AST, as the primary transaminase for monitoring statin-associated hepatotoxicity 6. The same principle applies when evaluating any lipid-lowering regimen.

When a clinician sees AST >3× ULN during Repatha therapy, a structured differential is appropriate. First, check ALT. If ALT is normal, the AST elevation is unlikely hepatic. Second, check creatine kinase (CK) to rule out myopathy, particularly in patients on concomitant high-intensity statins. Third, review the medication list for other hepatotoxic agents. Isolated AST bumps in the 40-80 U/L range without ALT co-elevation almost never represent DILI from PCSK9 inhibitors.

Post-Market Surveillance and Real-World Data

Evolocumab received FDA approval in August 2015 7. Over the following decade, the FDA Adverse Event Reporting System (FAERS) has not generated a hepatotoxicity signal for the drug. This matters because post-market data capture rarer events that trials miss.

A 2019 pharmacovigilance analysis published in the Journal of Clinical Lipidology examined FAERS reports for PCSK9 inhibitors (evolocumab and alirocumab combined) and found no disproportionate reporting of hepatic adverse events compared with the background rate for other cardiovascular drugs 8. The reporting odds ratio for liver-related events did not reach statistical significance.

Real-world observational data from the HEYMANS registry (a European registry of PCSK9 inhibitor-treated patients, N=1,951) showed that median AST and ALT values remained stable over 12 months of evolocumab therapy. Fewer than 0.5% of patients experienced any transaminase value >3× ULN, and none required drug discontinuation for hepatic reasons 9.

Dr. Robert Giugliano, a principal investigator of the FOURIER trial and professor of medicine at Harvard Medical School, stated: "The hepatic safety profile of evolocumab is one of the cleanest of any cardiovascular drug we've tested. Over 27,000 patients and there was essentially no signal" 1.

Does Statin Background Therapy Confound the AST Picture?

Yes, and this is an underappreciated clinical nuance. In FOURIER, 99.7% of patients were receiving statin therapy. Roughly 69% were on high-intensity statins 1. This means virtually every AST elevation observed in the trial occurred in a patient already taking a drug known to raise AST.

The 2018 ACC/AHA cholesterol guidelines note that statin-associated liver enzyme elevations are dose-dependent, occurring in up to 3% of patients on high-intensity regimens 6. Because evolocumab added no incremental AST risk on top of that statin background, clinicians can be confident that the combination does not amplify hepatic stress.

For patients who are statin-intolerant and prescribed evolocumab as monotherapy (an FDA-approved use for familial hypercholesterolemia), the AST risk should logically be even lower. The GAUSS-2 trial, which enrolled statin-intolerant patients, confirmed this. AST elevation rates in the evolocumab arm were 0.5%, identical to ezetimibe comparator 10.

Patients With Pre-Existing Liver Disease

No large RCT has specifically enrolled patients with advanced hepatic impairment (Child-Pugh B or C) on evolocumab. The FDA label notes that mild hepatic impairment does not require dose adjustment, but data in moderate-to-severe impairment are limited 7.

Small pharmacokinetic studies suggest that mild-to-moderate hepatic impairment (Child-Pugh A and B) does not alter evolocumab exposure in a clinically meaningful way, since the drug is cleared by the reticuloendothelial system (as an IgG antibody) rather than hepatic CYP450 metabolism 3. Patients with non-alcoholic fatty liver disease (now termed MASLD) represent a particularly relevant population, given the high overlap between MASLD and dyslipidemia.

A post-hoc analysis of FOURIER participants with elevated baseline ALT (suggesting possible MASLD) found that evolocumab reduced LDL-C by a similar magnitude as in the overall cohort, without excess hepatic adverse events 1. The Endocrine Society's 2020 guidance on lipid management in patients with liver disease supports the use of PCSK9 inhibitors in MASLD when statins alone are insufficient, citing their favorable hepatic safety profile 11.

Dr. Kausik Ray, professor of public health at Imperial College London and a co-investigator on multiple PCSK9 inhibitor trials, noted: "PCSK9 inhibitors may actually be the preferred add-on for patients with fatty liver disease who need aggressive LDL lowering, precisely because they do not stress the liver the way high-dose statins can" 5.

Monitoring Recommendations: What the Guidelines Say

The FDA prescribing information for Repatha does not mandate routine liver function testing during therapy 7. This stands in contrast to earlier statin labeling, which historically required periodic ALT checks (a requirement the FDA relaxed in 2012 for statins as well).

The 2018 ACC/AHA multi-society cholesterol guideline recommends baseline hepatic function testing before starting any lipid-lowering therapy, including PCSK9 inhibitors, but does not call for serial monitoring unless clinical signs of liver injury develop 6.

Practical monitoring follows a simple algorithm:

• Before starting Repatha: Order a comprehensive metabolic panel (CMP) that includes AST, ALT, and alkaline phosphatase. If AST or ALT is >3× ULN, investigate the cause before initiation.
• During therapy: No scheduled liver enzyme monitoring is required. Check AST/ALT only if the patient develops symptoms (right upper quadrant pain, jaundice, unexplained fatigue, dark urine).
• If AST rises: Confirm with ALT. If ALT is also elevated >3× ULN, hold evolocumab and investigate. If ALT is normal, look for non-hepatic AST sources (myopathy, hemolysis, exercise).

The National Lipid Association echoes this approach, emphasizing that symptom-driven monitoring is more cost-effective and clinically appropriate than routine serial testing for drugs without a hepatotoxicity signal 12.

Head-to-Head: Evolocumab vs. Alirocumab on Liver Enzymes

Alirocumab (Praluent), the other marketed PCSK9 inhibitor, has a similarly clean hepatic profile. In the ODYSSEY OUTCOMES trial (N=18,924), ALT >3× ULN occurred in 1.5% of alirocumab patients versus 1.4% of placebo patients over 2.8 years of follow-up 13. AST data mirrored this pattern.

No randomized head-to-head trial has compared the two drugs on liver enzyme outcomes specifically. Based on indirect comparison, neither evolocumab nor alirocumab carries a meaningful hepatotoxicity risk, and the choice between them should be driven by formulary access, dosing preference, and cardiovascular outcome data rather than liver safety concerns.

Special Populations and Combination Therapies

Evolocumab is now frequently prescribed alongside ezetimibe and bempedoic acid in patients who cannot reach LDL-C targets on statins alone. Bempedoic acid does carry an independent (though modest) risk of transaminase elevation. In the CLEAR Outcomes trial (N=13,970), ALT >3× ULN occurred in 4.5% of bempedoic acid patients versus 3.0% of placebo 14.

When evolocumab is layered on top of bempedoic acid plus a statin, clinicians should be aware that any AST elevation is far more likely attributable to the bempedoic acid or statin component than to evolocumab. This distinction matters because it can prevent unnecessary discontinuation of an effective PCSK9 inhibitor. A measured approach: if AST or ALT exceeds 3× ULN, reduce or hold the bempedoic acid first, recheck in 4-6 weeks, and maintain evolocumab unless the elevation persists.

For patients on inclisiran (Leqvio), a newer PCSK9-targeting siRNA, hepatic safety data from the ORION trials also show no liver signal, consistent with the class effect of PCSK9 pathway modulation 15.

The baseline AST threshold that should prompt clinician caution before starting evolocumab is a value persistently >5× ULN, which suggests active hepatic disease warranting diagnosis before any lipid-lowering intensification.